JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2004; 44:980-987, doi:10.1016/j.jacc.2004.05.059
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gibson, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gibson, C. M.

ACUTE MYOCARDIAL ISCHEMIA/INFARCTION

Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with st-segment elevation myocardial infarction

C. Michael Gibson, MS, MD*,*, Sabina A. Murphy, MPH*, Ajay J. Kirtane, MD*,{dagger}, Robert P. Giugliano, MD, SM*, Christopher P. Cannon, MD*, Elliott M. Antman, MD*, Eugene Braunwald, MD* TIMI Study Group

* TIMI Study Group, Cardiovascular Division, Brigham & Women's Hospital
{dagger} Cardiovascular Division, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, MassachusettsUSA

Manuscript received March 12, 2004; revised manuscript received May 6, 2004, accepted May 11, 2004.

* Reprint requests and correspondence: Dr. C. Michael Gibson, 350 Longwood Avenue, First Floor, Boston, Massachusetts 02115 (Email: mgibson{at}timi.org).

OBJECTIVES: We sought to determine if an underlying mechanism of the association between prolonged symptom-to-treatment times and adverse outcomes may be an association of symptom-to-treatment times with impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades (TMPGs).

BACKGROUND: Prolonged symptom duration among ST-segment elevation myocardial infarction (STEMI) patients undergoing fibrinolytic therapy is associated with adverse outcomes.

METHODS: Angiography was performed 60 min after fibrinolytic administration in 3,845 Thrombolysis In Myocardial Infarction (TIMI) trial patients.

RESULTS: The median time from symptom onset to treatment was longer among patients with impaired myocardial perfusion (3.0 h for TMPG 0/1 vs. 2.7 h for TMPG 2/3; p = 0.001). In a multivariate model, impaired tissue perfusion (TMPG 0/1) remained associated with increased time to treatment (odds ratio1.14 per hour of delay; p = 0.007) even after adjusting for Thrombolysis In Myocardial Infarction flow grade (TFG) 3, left anterior descending infarct location, and baseline clinical characteristics. Impaired myocardial perfusion after rescue/adjunctive percutaneous coronary intervention (PCI) was associated with longer median times to treatment (3.0 h for TMPG 2/3 vs. 2.7 h for TMPG 0/1; p = 0.017), as was abnormal epicardial flow after rescue/adjunctive PCI (3.3 h for TFG 0/1/2 vs. 2.8 h for TFG 3; p = 0.005). Thirty-day mortality was associated with longer time from onset of symptoms to treatment (6.6% mortality for time to treatment >4 h vs. 3.3%; p < 0.001), even among patients undergoing rescue PCI.

CONCLUSIONS: A prolonged symptom to treatment time among STEMI patients is associated with impaired myocardial perfusion independent of epicardial flow both immediately after fibrinolytic administration and after rescue/adjunctive PCI. These data provide a pathophysiologic link between prolonged symptoms due to vessel occlusion, impaired myocardial perfusion, and poor clinical outcomes.

Abbreviations and Acronyms
  CHF = congestive heart failure
  CTFC = corrected Thrombolysis In Myocardial Infarction frame count
  LAD = left anterior descending
  PCI = percutaneous coronary intervention
  OR = odds ratio
  rt-PA = recombinant tissue-type plasminogen activator
  STEMI = ST-segment elevation myocardial infarction
  TFG = Thrombolysis In Myocardial Infarction flow grade
  TIMI = Thrombolysis In Myocardial Infarction
  TMPG = Thrombolysis In Myocardial Infarction myocardial perfusion grade
  TNK = tenecteplase
  t-PA = tissue-type plasminogen activator




This article has been cited by other articles:


Home page
Arch Intern MedHome page
H. H. Ting, E. H. Bradley, Y. Wang, J. H. Lichtman, B. K. Nallamothu, M. D. Sullivan, B. J. Gersh, V. L. Roger, J. P. Curtis, and H. M. Krumholz
Factors Associated With Longer Time From Symptom Onset to Hospital Presentation for Patients With ST-Elevation Myocardial Infarction
Arch Intern Med, May 12, 2008; 168(9): 959 - 968.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. P. Wharton Jr, E. C. Keeley, C. L. Grines, T. P. Wharton Jr, E. C. Keeley, and C. L. Grines
The Case for Community Hospital Angioplasty
Circulation, November 29, 2005; 112(22): 3509 - 3534.
[Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al.
Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Eur. Heart J., April 2, 2005; 26(8): 804 - 847.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2004 by the American College of Cardiology Foundation.